Company:  TYME TECHNOLOGIES, INC. (TYME)
Form Type:  4
Filing Date:  1/14/2020 
CIK:  0001537917 
Address:  17 STATE STREET
7TH FLOOR
 
City, State, Zip:  NEW YORK, New York 10004 
Telephone:  212-461-2315 
Fiscal Year:  03/31 
Last Trade
Last Trade: 
$1.93  
Change: 
-0.02 (-1.03%)  
Trade Time: 
Jan 17  
Market Cap: 
$217.19M
Trade TYME now with

© 2020  
Description of Business
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients' quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific pathways within cancer, TYME's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic requirements to cause cancer cell death. Our lead clinical CMBT program, SM-88 (racemetyrosine), is a novel, oral, monotherapy investigational agent that has been studied in clinical trials for over five years within more than 150 cancer patients. TYME recently completed enrollment for two Phase II clinical trials in prostate and pancreatic cancer, and the Company is preparing for pivotal studies for SM-88 in pancreatic cancer during the second half of calendar year 2019.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    REPORTING OWNERS
    SIGNATURES
  EXHIBIT 24
    LIMITED POWER OF ATTORNEY